-
2023-508473-86-00
3
metastatic prostate cancer
-
2024-512754-16-00
5
Prostate cancer
-
2023-509729-33-00
1
Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory
-
2024-512511-49-00
4
Early triple-negative breast cancer (TNBC)
-
2024-514057-30-00
3
cell lung carcinoma
-
2024-514144-85-02
3
Glioblastoma
-
2024-516182-37-01
4
Maintenance treatment in patients with locally advanced/metastatic uro
-
2024-517339-30-00
7
Advanced Solid Tumors
-
2024-520140-42-00
5
Patients with primary HPV high-grade squamous intra-epithelial lesions
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521437-88-00
4
head and neck squamous cell carcinoma
-
2025-521619-37-00
5
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
-
2025-521982-29-00
4
Adult patients with advanced hormone receptor positive (HR+), HER2- br
-
2025-522318-21-00
7
Neoplasms, Colorectal
-
2025-522723-98-00
9
solid tumor
-
2025-522801-39-00
4
Stage III Non Small Cell Lung Cancer
-
2025-523432-39-01
9
Advanced KRAS G12D-Mutant Solid Tumors
-
2025-523537-26-00
9
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
-
2025-523590-42-00
7
Locally Advanced or Metastatic Solid Tumors
-
2025-523895-22-00
4
Non-small cell lung cancer (NSCLC)
-
2025-523913-27-00
5
Participants with R0/R1 resected liver metastases from colorectal canc
-
2025-520565-51-00
5
2026-06-23
small cell lung cancer
-
2025-524620-22-00
9
2026-06-22
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
-
2025-524843-11-00
4
2026-06-15
Non-Small Cell Lung Cancer